Evidence map›Paper›PMID 33503889›Full record

ReviewPharmaceutics2021

Nanomaterials for Protein Delivery in Anticancer Applications.

Anne Yau, Jinhyung Lee, Yupeng Chen

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 60 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Anne YauDepartment of Biomedical Engineering, University of Connecticut, Storrs, CT 06269, USA.
Jinhyung LeeDepartment of Biomedical Engineering, University of Connecticut, Storrs, CT 06269, USA.ORCID 0000-0002-8058-3511
Yupeng ChenDepartment of Biomedical Engineering, University of Connecticut, Storrs, CT 06269, USA.
University of Connecticut · US

Funding

Supplement: Developing Nanomaterial Platform for Intra-Cartilage Delivery of RNA Therapeutics against Joint DiseasesR01AR072027 · NIAMS · UNIVERSITY OF CONNECTICUT STORRS · PI CHEN, YUPENG · 2017 to 2022
$2.3M
Growth Plate Cartilage Repair via Novel Matrilin3/Rosette Nanotube Hybrid MatrixR03AR069383 · NIAMS · UNIVERSITY OF CONNECTICUT STORRS · PI CHEN, YUPENG · 2016 to 2018
$242k
National Science Foundation 1905785NIAMS NIH HHS R01 AR072027NIAMS NIH HHS R03 AR069383NIH HHS 7R01AR072027NIH HHS 7R03AR069383
6 · The paper itself

Abstract

Nanotechnology platforms, such as nanoparticles, liposomes, dendrimers, and micelles have been studied extensively for various drug deliveries, to treat or prevent diseases by modulating physiological or pathological processes. The delivery drug molecules range from traditional small molecules to recently developed biologics, such as proteins, peptides, and nucleic acids. Among them, proteins have shown a series of advantages and potential in various therapeutic applications, such as introducing therapeutic proteins due to genetic defects, or used as nanocarriers for anticancer agents to decelerate tumor growth or control metastasis. This review discusses the existing nanoparticle delivery systems, introducing design strategies, advantages of using each system, and possible limitations. Moreover, we will examine the intracellular delivery of different protein therapeutics, such as antibodies, antigens, and gene editing proteins into the host cells to achieve anticancer effects and cancer vaccines. Finally, we explore the current applications of protein delivery in anticancer treatments.

Indexed as

anticancer therapycancer treatmentnanomaterialsnanotechnologyprotein delivery

Identifiers

PMID33503889
PMCPMC7910976
OpenAlexW3124201767

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.